SmartTRAK, the leading provider of market data and analysis for the wound and regenerative medicine markets, recently reported on current trends and the focus on differentiation in the wound care space. The report noted that Biologics is garnering attention through data and stated that “Autologous solutions for hard-to-heal wounds are gaining attention. To date, Reapplix has the strongest clinical data with a 269-patient diabetic foot ulcer (DFU) clinical study demonstrating a significant increase in healing at 20 weeks compared to standard of care.”
